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Abstract
Background: Azithromycin is an azalide antibiotic with an extensive range of indications and has
become a common treatment option due to its convenient dosing regimen and therapeutic
advantages. Human studies addressing gestational use of azithromycin have primarily focused on
antibiotic efficacy rather than fetal safety. Our primary objective was to evaluate the possibility of
teratogenic risk following gestational exposure to azithromycin.
Methods: There were 3 groups of pregnant women enrolled in our study: 1) women who took
azithromycin. 2) women exposed to non-teratogenic antibiotics for similar indications, and 3)
women exposed to non-teratogenic agents. They were matched for gestational age at time of call,
maternal age, cigarette and alcohol consumption. Rates of major malformations and other
endpoints of interest were compared among the three groups.
Results: Pregnancy outcome of 123 women in each group was ascertained. There were no
statistically significant differences among the three groups in the rates of major malformations; 3.4%
(exposed) versus 2.3% (disease matched) and 3.4% (non teratogen) or any other endpoints that
were examined. In the azithromycin group, 88 (71.6%) women took the drug during the first
trimester
Conclusion: Results suggest that gestational exposure to azithromycin is not associated with an
increase in the rate of major malformations above the baseline of 1–3%. Our data adds to previous
research showing that macrolide antibiotics, as a group, are generally safe in pregnancy and
provides an evidence-based option for health professionals caring for populations with chlamydia.
Background
Azithromycin (Zithromax®) is an azalide antibiotic
belonging to a subclass of macrolide antibiotics devel-
oped as an alternative treatment to improve the spectrum
of activity and to eliminate some of the clinical disadvan-
tages associated with other macrolides [1]. Structural
modification resulting from substitution of a nitrogen
atom on the lactone ring with a methyl group, protects
azithromycin from breakdown by gastric acidity and
thereby increases its elimination half-life [2], making it
possible for single dose therapy. Its unique pharmacoki-
netic properties offer additional clinical advantages that
include a substantial reduction of gastrointestinal side
effects and increased patient compliance due to more con-
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venient dosing regimens. Its main indications for use
include treatment of mild to moderate infections of the
upper and lower respiratory tract, [1] as well as skin infec-
tions [3]. Azithromycin is also highly effective against uro-
genital infections such as Chlamydia [4] and gonorrhea [5]
when administered as a single one-gram dose. As well, its
anti-inflammatory role in cystic fibrosis was also estab-
lished [6]. Recently, a large study examining treatment of
trachomas(almost 1000 people) was published, that doc-
umented that the prevalence and intensity of infection fell
dramatically and remained low for two years after one
treatment[7].
Animal reproductive studies found no evidence of
impaired fertility or harm to the fetus following azithro-
mycin exposure [8-10]. Only limited information on the
effects of azithromycin use during human pregnancy is
available. One study suggested that azalide macrolide was
associated with limited transplacental transfer as only
2.6% of the drug that reached the maternal arterial side
crossed the placenta. [11].
Although several studies are available on the gestational
use of azithromycin, the focus of these studies was to
establish the efficacy rather than to examine its safety in
pregnancy [12-16]. Effectiveness of the drug for numerous
indications were well established in these reports, how-
ever no information was provided regarding the gesta-
tional age at time of exposure or pregnancy outcomes.
There was an observational cohort study that described
the outcomes of pregnancies in women who were pre-
scribed newly marketed drugs by their general practition-
ers. There were 11 reported exposures to azithromycin
during the first trimester, resulting in one elective abor-
tion, one ectopic pregnancy and 10 healthy, full-term
babies[17]. Another study investigating the efficacy of azi-
thromycin in reducing lower genital ureaplasma coloniza-
tion in 32 women at risk of pre-term delivery found no
adverse neonatal outcomes [18]. Finally, two cases of
women with scrub typhus treated successfully with three-
day courses of azithromycin in the second trimester
reported healthy pregnancy outcomes [19].
All of these primary infections that are treated with azi-
thromycin are common among women of child bearing
age, and coupled with the fact that at least 50 percent of
pregnancies are unplanned, 8 the likelihood of azithro-
mycin being prescribed during pregnancy is very high.
Consequently, there is a need for evidence-based data
related to the fetal safety of azithromycin. Our primary
objective was to ascertain if there is an increased risk of
major malformations (above the baseline risk of 1–3%)
in women exposed to azithromycin during pregnancy.
Secondary outcomes of interest included rates of sponta-
neous abortions, fetal distress, gestational age at birth and
mean birth weight.
Methods
The Motherisk Program, is a teratogen information service
at The Hospital for Sick Children in Toronto, Canada,
where women and their health care providers can call to
receive information regarding exposures during preg-
nancy such as drugs, chemicals, radiation and infectious
diseases. If a woman was currently pregnant and taking
azithromycin, she was asked if she would be interested in
enrolling in a study where the outcome of her pregnancy
would be followed up.
At the initial interview, a standardized intake form was
completed, which recorded details of maternal demo-
graphics, medical and obstetrical histories, concurrent
drug use, and other exposures. In addition, informed con-
sent was provided by the woman to allow for follow-up
following the birth of her baby.
All the women were contacted by the time the infant was
a year old. After completion of the standardised question-
naire that was used to record details of the baby's birth
and subsequent health, the mothers were requested to
give permission for the interviewer to send a letter to the
child's physician, to confirm the medical details they had
provided, to eliminate any possible bias by only relying
on the mother's report.
Women exposed to azithromycin were compared to two
comparison groups consisting of women not exposed to
azithromycin who were matched by maternal age (± 2
years), gestational age at the time of call (± 2 weeks), alco-
hol and cigarette use. Comparison group #1 (disease
matched) consisted of women with similar infections,
who had used other antibiotics, which are considered safe
to use during pregnancy (erythromycin, amoxicillin, clar-
ithromycin, clindamycin). The second comparison group
consisted of women exposed to non-teratogenic drugs
(acetaminophen, and other over-the-counter medica-
tions) who did not have an infection. Rates of major mal-
formations and secondary outcomes of interest were
compared among the three groups. A major malformation
was defined as any anomaly that has an adverse effect on
either the function or the social acceptability of the child
[20]. Other pregnancy outcomes including spontaneous
abortion(SA), therapeutic abortion (TA). Fetal death and
other complications were also compared. This protocol
was approved by the Research Ethics Board at the Hospital
for Sick Children.
Continuous data among patients and control subjects
were compared using one-way analysis of variance
(ANOVA). The Kruskal Wallice rank sum test was used toBMC Pregnancy and Childbirth 2006, 6:18 http://www.biomedcentral.com/1471-2393/6/18
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compare continuous data that did not follow normal dis-
tribution. Categorical data were compared by χ2 analysis
or Fisher's exact test, whenever appropriate.
Results
The outcome of 123 pregnancies with gestational use of
azithromycin was ascertained as well as 123 in each of two
comparison groups. In the azithromycin group, 88 (72%)
exposures occurred during the first trimester, 23 (19%) in
the second trimester, and 12 (9%) in the third trimester.
Five women used the drug more than once, due to recur-
rent infections during the pregnancy. The indication for
azithromycin use among the exposed group, were for the
most part, respiratory infections (82%) including bron-
chitis, sinusitis and pneumonia, whereas only 18% of the
women used azithromycin for genitourinary infections.
Treatment for chlamydia was with a single one-gram oral
dose of azithromycin, with no further recurrences. The
average treatment for URTI's was for 5 days: day one 250
mg 2/d and day 2–5 250 mg 1/d. There were no differ-
ences in the maternal characteristics between the study
group and the two comparison groups.
The outcomes in the exposed group were 113 live births;
6 spontaneous abortions; 3 fetal deaths and 1 therapeutic
abortion (for which no anomalies were detected). There
were no significant differences in the rates of major mal-
formations between women exposed to azithromycin
(3.4%), and those in the disease-matched and non-tera-
togen (2.3% and 3.4%, respectively). Table 1
The details of the major malformations are documented
in Table 2. Of note, the three malformations in the
exposed group, were in the children of mothers who were
treated with azithromycin for URTI. Statistical analysis of
secondary outcomes did not detect differences among the
three groups in terms of pregnancy outcome, fetal distress,
preterm delivery rates, and mean birth weight. Table 1
Discussion
To our knowledge, this is the first prospective study that
evaluated the fetal safety of azithromycin use during preg-
nancy. We feel that it confirms, as with the macrolides,
that this drug appears to be relatively safe for use during
pregnancy[21,22].
Single-dose azithromycin therapy presents a distinct
advantage over multiple doses of other antibiotics, and it
appears to be the most cost-effective agent for many indi-
cations [23]. This is particularly true in the case of adoles-
cent patients and asymptomatic infections, where many
patients are unlikely to comply with multi-dose therapy
[24]. The combination of increased efficacy, increased
compliance, and fewer adverse effects than with other
macrolide antibiotics, often makes azithromycin a pre-
ferred prescribing option for physicians [25]. However, a
lack of evidence-based data regarding the safety of the
drug often forces health-care providers to face the predic-
ament of estimating the reproductive risks [26] The cur-
rent recommendations of the Centre for Disease Control
in the United States list azithromycin as a drug of choice
Table 1: Pregnancy Outcomes
Variables Azithromycin Disease-
matched
Non-
teratogens
Azithromycin vs. 
antibiotics
Azithromycin vs. 
Non-teratogens
Three 
groups
P-value 
overall
N% N % N % χ2 (df = 1) P χ2 (df = 1) P χ2 (df = 2) P
Live Birth 113 91.9 117 95.1 114 92.7 0.01 0.92 0.95 0.33 0.58 0.75
SA 6 4.9 3 2.4 8 6.5 0.92 0.34 0.04 0.85 2.34 0.31
Fetal Distress 19 16.8 24 20.5 26 22.8 5.70 0.02 0.64 0.42 1.72 0.42
Major malformation 3 3.4 2 2.3 3 3.4 0.89
Mean SD Mean SD Mean SD χ2 (df = 2)
Gest age @birth (wks) 39 2 39 2 40 1 0.56 0.76
Birth wt (g) 3460 587 3522 491 3546 501 1.29 0.52
Table 2: Malformations
AZITHROMYCIN-EXPOSED GROUP • Sensory neural deafness (profound congenital)
• Tracheomalacia, incompetent oesophageal sphincter and gastroesophageal reflux
• Congenital diaphragmatic hernia
DISEASE-MATCHED GROUP • Ductus arteriosus persistence
• Hydronephrosis of the left kidney
NON-TERATOGEN GROUP • VSD
• Hypospadias
• Diaphragmatic herniaBMC Pregnancy and Childbirth 2006, 6:18 http://www.biomedcentral.com/1471-2393/6/18
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for the non-pregnant population, but as an alternative
therapy for the pregnant patient [27].
Sexually transmitted diseases may be acquired or become
apparent during pregnancy, [28] consequently, it is criti-
cal that screening and treatment for infections such as
syphilis, gonorrhea and chlamydia be conducted to pre-
vent both maternal and fetal morbidity and mortality
[29]. Genital infections may remain undiagnosed during
pregnancy, as they are often asymptomatic. Subsequently,
consequences of treatment failure during pregnancy can
be of greater concern as serious sequelae can result,
including increased rates of pregnancy loss, low birth
weight, preterm birth, neonatal mortality and congenital
infections. In the case of chlamydia-infected populations,
the benefits of treating the infection, potentially outweigh
the possible risks associated with the drug, given that peri-
natal transmission of the infection can be of great con-
cern.
The main limitation of this study is the small sample size,
as it only had an 80% power to detect a 4.5-fold increase
in the rate of major malformations with alpha value of
0.05. Approximately 800 cases in each group would be
required to detect a two-fold increase in risk of relatively
common malformations and thousands would be
required to detect rare defects. However, despite the rela-
tively small sample size, we had 2 other groups of women
to make comparisons, thereby strengthening the limited
power of the study.
Of note, all 15 women in our study who were prescribed
azithromycin for chlamydia infections chose to initiate its
use after being informed of the possible concerns if the
infection was left untreated during their pregnancy. In
contrast, most women taking the drug to treat respiratory
infections consisted of primarily inadvertent exposures or
second-line therapy.
Conclusion
The results of this prospective study of 123 pregnant
women exposed to azithromycin do not suggest that there
is a greater risk for major malformations above the base-
line rate of 1%–3%. This evidence-based data will be par-
ticularly useful for health care providers in their decision-
making, regarding the treatment of pregnant women for
infections such as chlamydia when azithromycin is con-
sidered to be the drug of choice.
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